Invesco Biotechnology & Genome ETF
PBE
100 hedge funds and large institutions have $81M invested in Invesco Biotechnology & Genome ETF in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 12 closing their positions.
1.2% less ownership
Funds ownership: 34.08% → 32.88% (-1.2%)
7% less funds holding
Funds holding: 108 → 100 (-8)
8% less capital invested
Capital invested by funds: $88.2M → $81M (-$7.25M)
17% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 29
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Top Buyers
Top Sellers
PBE Hedge Fund Activity: Q1 2026 in Review
100 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2026, worth a combined $81M — down 8.2% from $88.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PBE and 8 opened new positions — a net loss of 4 holders — while 29 trimmed existing stakes and 24 added.
The largest buyer was Royal Bank of Canada, adding an estimated $987K. The largest seller was Q3 Asset Management, exiting entirely with an estimated $1.43M sold.
- 100 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2026, down from 108 in Q4 2025.
- Funds reported $81M of Invesco Biotechnology & Genome ETF stock for Q1 2026, down 8.2% quarter-over-quarter.
- 8 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2026 and 12 closed out, a net change of -4 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q1 2026 was Royal Bank of Canada, an estimated $987K added.
- The largest Invesco Biotechnology & Genome ETF seller in Q1 2026 was Q3 Asset Management, an estimated $1.43M sold.
Based on aggregated 13F filings for Q1 2026.